holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than July 17, 1998.

A. Federal Reserve Bank of Atlanta (Lois Berthaume, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303-2713:

1. Patricia McLaurin Morgan, Richard Brand Morgan, Paul Mangum Morgan, all of Lawrenceville, Georgia; to acquire voting shares of Brand Banking Company, Lawrenceville, Georgia.

Board of Governors of the Federal Reserve System, June 25, 1998.

Robert deV. Frierson,

Associate Secretary of the Board. [FR Doc. 98–17454 Filed 6–30–98; 8:45 am] BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than July 27, 1998.

A. Federal Reserve Bank of New York (Betsy Buttrill White, Senior Vice President) 33 Liberty Street, New York, New York 10045-0001:

1. CNY Financial Corporation, Cortland, New York; to become a bank holding company by acquiring Cortland Savings Bank, Cortland, New York.

Board of Governors of the Federal Reserve System, June 25, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.
[FR Doc. 98–17455 Filed 6–30–98; 8:45 am]
BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than July 27, 1998.

A. Federal Reserve Bank of Chicago (Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. Old Kent Financial Corporation,
Grand Rapids, Michigan; to merge with

First Evergreen Corporation, Evergreen Park, Illinois, and thereby indirectly acquire First National Bank of Evergreen Park, Evergreen Park, Illinois.

B. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63102-2034:

1. First Banks, Inc., Creve Coeur, Missouri; and its wholly owned subsidiary CCB Bancorp, Inc., Newport Beach, California; to acquire 100 percent of the voting shares of Republic Bank, Torrance, California.

Board of Governors of the Federal Reserve System, June 26, 1998.

Jennifer J. Johnson.

Secretary of the Board.
[FR Doc. 98–17527 Filed 6-30-98; 8:45 am]
BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than July 17, 1998.

A. Federal Reserve Bank of Boston (Richard Walker, Community Affairs Officer) 600 Atlantic Avenue, Boston, Massachusetts 02106-2204:

1. BankBoston Corporation (BKB), Boston, Massachusetts; to acquire Robertson Stephens, Inc., San Francisco, California, and thereby engage in underwriting and dealing to a limited extent in all types of equity securities, other than ownership interest in openend investment companies; making, acquiring and servicing loans and other extensions of credit, pursuant to § 225.28(b)(1) of Regulation Y; providing investment and financial advisory services, pursuant to § 225.28(b)(6) of Regulation Y; arranging commercial or industrial real estate equity financing, pursuant to § 225.28(b)(2)(ii) of Regulation Y; underwriting and dealing in obligations of the United States and Canada, general obligations of U.S. States, Canadian provinces, and their political subdivisions, and other obligation in which state member banks may underwrite and deal under 12 U.S.C. 24 and 335, pursuant to § 225.28(b)(8) of Regulation Y; and providing securities brokerage, private placement, and riskless principal services, pursuant to § 225.28(b)(7)(i), (ii), and (iii) of Regulation Y. The proposed activities are currently being conducted, directly or indirectly, by the subject entities with Board approval. (See Bank of Boston Corp., 83 Fed. Res. Bull. 42 (1997) and Bank America Corp., 83 Fed. Res. Bull. 1008 (1997))

Board of Governors of the Federal Reserve System, June 25, 1998.

Robert deV. Frierson,

Associate Secretary of the Board. [FR Doc. 98–17453 Filed 6–30–98; 8:45 am] BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct; Terry D. Reisine, Ph.D.

AGENCY: Office of the Secretary, HHS. **ACTION:** Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Terry D. Reisine, Ph.D., University of Pennsylvania: Based upon "The Dean's Proposed Findings of Fact" and "Memorandum on Issues Not Fully Addressed in Findings of Fact," forwarded to ORI by the University of Pennsylvania, dated October 25, 1996 (Findings and Memorandum), and ORI's oversight review of the evidence provided, ORI finds that Terry D. Reisine, Ph.D., former Professor, Department of Pharmacology, University of Pennsylvania, engaged in scientific misconduct in biomedical

research supported by Public Health Service (PHS) grants.

Specifically, ORI finds that the Respondent falsified results related to the measurement of cyclic AMP in cultured, transfected cells by falsely representing in manuscripts and publications the number of experiments conducted, and by falsifying and/or fabricating some of the substantive data presented in those manuscripts and publications. Moreover, ORI finds that the Respondent attempted to falsify data by directing members of his laboratory to construct figures and tables with false values in the preparation of manuscripts.

Dr. Reisine has entered into a Voluntary Exclusion Agreement with ORI. The settlement is not an admission of liability on the part of the Respondent, and Dr. Reisine denies having committed scientific misconduct. Pursuant to the Agreement, Dr. Reisine has agreed to the following:

- (1) Respondent agreed to exclude himself voluntarily for a period of three (3) years beginning on June 11, 1998, from any contracting or subcontracting with any agency of the United States Government, and from eligibility for or involvement in nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR part 76 (Debarment Regulations).
- (2) Respondent agreed to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning on June 11, 1998.
- (3) Within 30 days of the effective date of the Agreement, Respondent agreed to submit letters to the following journals requesting correction of the corresponding articles. The corrections are warranted by the following findings of the Findings and Memorandum:

a. The Journal of Biological Chemistry

Kong, H., Raynor, K., Yasuda, K., Moe, S.T.,
Portoghese, P.S., Bell, G.I., and Reisine,
T. "A single residue, aspartic acid 95, in
the gamma opioid receptor specifies
selective high affinity agonist binding."
J. Biol. Chem. 268:23055–23058, 1993.

- i. The results in Table 1 are stated in the table legend to be based on four (4) experiments with calculated SEM values and Hill coefficients when, in fact, the majority of the listed compounds were tested only once, and a few tested only twice.
- ii. Figure 2 data are stated in the figure legend to be the means of three (3) different experiments when, in fact, most of the results were based on a single experiment.

b. The Journal of Pharmacology and Experimental Therapeutics

- Raynor, K., Kong, H., Hines, J., Kong, G., Benevoc, J., Yasuda, K., Bell, G.I., and Reisine, T. "Molecular mechanisms of agonist-induced desensitization of the cloned mouse kappa opioid receptor." J. Pharmacol. Exp. Ther. 270:1381–1386, 1994.
- i. The figure legend for Figures 3A, 3C, and 3D claimed that the values shown were the average of three (3) different experiments when, in fact, the results were from only one (1) experiment.
- ii. The figure legend for Figure 4B claimed that the values shown were the average of four (4) different experiments when, in fact, the results were from only three (3) experiments.
- iii. Figures 3A, 3C, and 3D each show several levels of adenyl cyclase inhibition that do not reflect the actual results obtained in duplicate cyclic AMP assays.

c. Molecular Pharmacology

- Reisine, T., Kong, H., Raynor, K., Yano, H., Takeda, J., Yasuda, K., and Bell, G.I. "Splice variant of the somatostatin receptor 2 subtype, somatostatin receptor 2B, couples to adenylyl cyclase." Mol. Pharmacol. 44:1016–1020, 1994.
- i. The legend for Figure 3A claims that three (3) experiments were performed when, in fact, only two (2) experiments were performed for the SSTR2B mutants.
- ii. The legend for Figure 3B claims that the values presented are the average of two (2) different experiments when, in fact, the inhibition curve shown was based on a single experiment.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Dorothy K. Macfarlane,

Acting Director, Office of Research Integrity. [FR Doc. 98–17411 Filed 6–30–98; 8:45 am] BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[Program Announcement 98095]

Enhancement of Local Public Health Departments Participation in Brownfields Decisions and Actions; Notice of Availability of Funds

Introduction

The Agency for Toxic Substances and Disease Registry (ATSDR) announces the availability of fiscal year (FY) 1998 funds for a cooperative agreement program for a pilot activity with a select number of local health departments to demonstrate effective public health